PL3826679T3 - Związki indukujące ABCA1 do stosowania w leczeniu chorób nerek - Google Patents
Związki indukujące ABCA1 do stosowania w leczeniu chorób nerekInfo
- Publication number
- PL3826679T3 PL3826679T3 PL19749657.3T PL19749657T PL3826679T3 PL 3826679 T3 PL3826679 T3 PL 3826679T3 PL 19749657 T PL19749657 T PL 19749657T PL 3826679 T3 PL3826679 T3 PL 3826679T3
- Authority
- PL
- Poland
- Prior art keywords
- abca1
- treating kidney
- kidney disorders
- inducing compounds
- inducing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 208000017169 kidney disease Diseases 0.000 title 1
- 201000006370 kidney failure Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185871 | 2018-07-26 | ||
| PCT/EP2019/070251 WO2020021097A1 (en) | 2018-07-26 | 2019-07-26 | Compounds for use in treating kidney disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3826679T3 true PL3826679T3 (pl) | 2025-03-10 |
Family
ID=63077813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19749657.3T PL3826679T3 (pl) | 2018-07-26 | 2019-07-26 | Związki indukujące ABCA1 do stosowania w leczeniu chorób nerek |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200085810A1 (pl) |
| EP (2) | EP4537901A3 (pl) |
| JP (2) | JP7478133B2 (pl) |
| KR (1) | KR102860768B1 (pl) |
| CN (2) | CN117736141A (pl) |
| AU (1) | AU2019310919B2 (pl) |
| CA (1) | CA3104793A1 (pl) |
| ES (1) | ES3005632T3 (pl) |
| IL (1) | IL280368B2 (pl) |
| MX (1) | MX2021000976A (pl) |
| PL (1) | PL3826679T3 (pl) |
| TW (1) | TWI891608B (pl) |
| WO (1) | WO2020021097A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| WO2022006277A1 (en) * | 2020-07-01 | 2022-01-06 | Angion Biomedica Corp. | Methods for treatment of fibrotic kidney diseases |
| US11814354B2 (en) * | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270846B (it) | 1993-05-10 | 1997-05-13 | Alfa Wassermann Spa | Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica. |
| US7030146B2 (en) | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
| DE602005009811D1 (de) | 2004-03-26 | 2008-10-30 | Hoffmann La Roche | Tetrahydrocarbazole und derivate |
| PL1756096T3 (pl) | 2004-05-03 | 2010-01-29 | Hoffmann La Roche | Pochodne indolilowe jako modulatory wątrobowych receptorów X |
| UA107088C2 (xx) | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| AR079022A1 (es) * | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| AR085013A1 (es) | 2011-01-26 | 2013-08-07 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| KR20140057652A (ko) | 2011-09-12 | 2014-05-13 | 에프. 호프만-라 로슈 아게 | Hdl-콜레스테롤 상승제로서의 3-피리딘 카복실산 하이드라자이드 |
| WO2014180741A1 (en) | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| EP3019168A1 (en) * | 2013-07-10 | 2016-05-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Losmapimod for use in treating glomerular disease |
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
-
2019
- 2019-07-25 US US16/522,116 patent/US20200085810A1/en not_active Abandoned
- 2019-07-26 EP EP24213767.7A patent/EP4537901A3/en active Pending
- 2019-07-26 TW TW108126640A patent/TWI891608B/zh active
- 2019-07-26 CN CN202311697211.0A patent/CN117736141A/zh active Pending
- 2019-07-26 WO PCT/EP2019/070251 patent/WO2020021097A1/en not_active Ceased
- 2019-07-26 PL PL19749657.3T patent/PL3826679T3/pl unknown
- 2019-07-26 CN CN201980048869.4A patent/CN112469442B/zh active Active
- 2019-07-26 JP JP2021504186A patent/JP7478133B2/ja active Active
- 2019-07-26 CA CA3104793A patent/CA3104793A1/en active Pending
- 2019-07-26 IL IL280368A patent/IL280368B2/en unknown
- 2019-07-26 MX MX2021000976A patent/MX2021000976A/es unknown
- 2019-07-26 ES ES19749657T patent/ES3005632T3/es active Active
- 2019-07-26 AU AU2019310919A patent/AU2019310919B2/en active Active
- 2019-07-26 KR KR1020217002388A patent/KR102860768B1/ko active Active
- 2019-07-26 EP EP19749657.3A patent/EP3826679B1/en active Active
-
2021
- 2021-03-19 US US17/206,955 patent/US20210275514A1/en not_active Abandoned
-
2024
- 2024-03-27 US US18/618,124 patent/US20240325372A1/en active Pending
- 2024-04-19 JP JP2024068208A patent/JP2024096989A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL280368B2 (en) | 2024-02-01 |
| JP2024096989A (ja) | 2024-07-17 |
| AU2019310919B2 (en) | 2025-04-03 |
| CA3104793A1 (en) | 2020-01-30 |
| JP7478133B2 (ja) | 2024-05-02 |
| KR20210038884A (ko) | 2021-04-08 |
| CN112469442A (zh) | 2021-03-09 |
| IL280368A (en) | 2021-03-25 |
| ES3005632T3 (en) | 2025-03-14 |
| AU2019310919A1 (en) | 2021-01-07 |
| JP2021531308A (ja) | 2021-11-18 |
| TWI891608B (zh) | 2025-08-01 |
| EP4537901A3 (en) | 2025-05-21 |
| US20210275514A1 (en) | 2021-09-09 |
| MX2021000976A (es) | 2021-03-31 |
| IL280368B1 (en) | 2023-10-01 |
| CN117736141A (zh) | 2024-03-22 |
| US20200085810A1 (en) | 2020-03-19 |
| EP3826679A1 (en) | 2021-06-02 |
| EP3826679B1 (en) | 2024-11-27 |
| KR102860768B1 (ko) | 2025-09-17 |
| TW202019486A (zh) | 2020-06-01 |
| WO2020021097A1 (en) | 2020-01-30 |
| US20240325372A1 (en) | 2024-10-03 |
| CN112469442B (zh) | 2024-04-09 |
| EP4537901A2 (en) | 2025-04-16 |
| EP3826679C0 (en) | 2024-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282663A (en) | BT1718 for use in cancer treatment | |
| IL256166B (en) | Compounds for use in the treatment of neuromuscular disorders | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| IL264641A (en) | Acetyl-leucine for use in the treatment of neurodegenerative diseases | |
| IL281052A (en) | Treatment of liver disorders | |
| IL251028A0 (en) | 17a,21-diesters of cortexolone for use in the treatment of tumors | |
| IL247699A0 (en) | Preparations and methods for the treatment of kidney disorders | |
| ZA201807653B (en) | New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions | |
| SG10201913400QA (en) | Methods for treating lung disorders | |
| IL280368A (en) | Compounds for use in the treatment of kidney disorders | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| SG11202010528XA (en) | Combinations for treating cancer | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| SG11202001134VA (en) | Clarifier for water treatment | |
| SG11202102878TA (en) | Treatment methods | |
| SG11202102827YA (en) | Treatment methods | |
| EP3664919C0 (en) | TANK FOR WATER TREATMENT | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL280424A (en) | Methods for treating neurodegenerative disorders | |
| GB201701404D0 (en) | Therapies for treating inflammatory disorders | |
| SG11202100269VA (en) | Compounds for use in the treatment of fascioliasis | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| GB201615844D0 (en) | Agents for use in therapy | |
| HK40102350A (zh) | 用於治疗肾脏疾患的化合物 | |
| IL276697A (en) | 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders |